PubMed Daily Triage Digest — 2026-07-09

Pipeline: v1.3 | Attempt: 1 of 3 | Run Status: SUCCESS
CRDT Window: 2026-07-08 → 2026-07-09 (incremental, last 24 h)
Articles triaged: 29 across 9 active topics (T2/CBC-ML: 0 results both primary and fallback)
PIPELINE articles: 15 | WATCH: 7 | SKIP: 7

⚡ TOP PICKS

T1 — Hematologic Malignancies

Search hits: 58 | Reviewed: 15 | HIGH: 3

🔴 PIPELINE — Score 10

PMID 42419338 · Lancet Haematol · 2026-07-08 · DOI
Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study
Daniels KP, Pounds SB, Wu H, Wang L, Alexander TB, Budhraja A, et al.

Phase 1 expansion of VENAML trial (NCT03194932) in 44 pediatric/young adult R/R AML patients. Venetoclax+cytarabine±idarubicin achieved 57% CR/CRi with 19/25 responders MRD-negative; 5.3-year median follow-up. Directly informs ongoing Phase 3 (NCT05183035). Highest-unmet-need setting in hematologic oncology.

🔴 PIPELINE — Score 8

PMID 42419755 · Br J Haematol · 2026-07-08 · DOI
Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from COG AHOD1331 trial
Casey DL, Renfro LA, Wu Y, McCarten K, Pei Q, Milgrom SA, et al.

COG RCT (n=340 pediatric stage IV HL). Bv-AVEPC improved 4-yr PFS vs ABVE-PC (HR 0.53) in most stage IV subtypes except bone marrow-only involvement (no PFS benefit). Lung-only: best prognosis (88.6%); bone marrow-only: worst (71.9%). Pattern-specific treatment guidance.

🔴 PIPELINE — Score 7

PMID 42420673 · Ann Hematol · 2026-07-09 · DOI
Baseline immunonutritional status drives CAR T-cell efficacy, survival, and safety in R/R lymphoma: validation of a pre-lymphodepletion PNI threshold
Zhang N, Yang F, Liu R, Fu Z, Li D, Guo Y, et al.

Retrospective cohort (n=449 R/R aggressive B-cell lymphoma, 33-month follow-up). Pre-lymphodepletion PNI >39.2 independently predicted ORR (65.5% vs 44.2%, p<0.001), 5-yr OS (59% vs 22%), and 5-yr PFS (43% vs 13%). Actionable simple biomarker for CAR-T candidate optimization.

🟡 WATCH — Score 5

PMID 42420551 · Discov Oncol · 2026-07-08
Leukemic architecture as a framework for risk stratification in NPM1-mutated AML — Narrative review; no original data.

PMID 42418831 · ACS Sens · 2026-07-08
Nanobiosensors for leukemia MRD monitoring — Review; femtomolar sensitivity claims; translational barriers unresolved.

T2 — CBC-Based Diagnostics and ML

Search hits: 0 (primary query) | Fallback hits: 0

No articles matching CBC/hematology-analyzer + ML terms entered PubMed CRDT 2026-07-08 to 2026-07-09. Topic passes through with zero candidates this cycle.

T3 — Early Cancer Detection (Liquid Biopsy, Screening)

Search hits: 36 | Reviewed: 15 | HIGH: 2

🔴 PIPELINE — Score 8

PMID 42419584 · Chest · 2026-07-08 · DOI
Lung Cancer Screening Centralization Is Associated With Improved Screening Uptake: The Veterans Healthcare Administration's Experience 2015-2021
Benjamin LN, Nunez ER, Chen L, Motwani Y, et al.

Nationwide VA retrospective cohort (n=151,194 Veterans, 2015-2021, difference-in-differences). Fully-centralized LCS programs: 75% higher uptake (IRR 1.75, 95% CI 1.49-2.07) vs decentralized. Persistent racial/rural disparities. Large-scale natural experiment informing LDCT program design.

🔴 PIPELINE — Score 7

PMID 42419775 · Eur Respir Rev · 2026-07-08 · DOI
Risk prediction for lung cancer screening: a systematic review and meta-regression
Rezaeianzadeh R, Leung C, Kim SJ, Choy K, Johnson KM, et al.

SR+meta-regression of 91 LC screening risk models (2020-2026). Biomarker-enhanced models outperform; <50% have external validation. Calls for validation over new model development.

🟡 WATCH — Score 5

PMID 42418618 · J Urol · 2026-07-08
Prostate cancer screening E-visits RCT (n=3,200, Kaiser Permanente) — Interactive personalized E-visit improves screening decisions; 15.6% completion rate limits generalizability.

⚪ SKIP — Score 4

PMID 42420761 · Biomed Chromatogr · Urine GC metabolomics for HCC detection review
PMID 42419530 · Crit Rev Oncol Hematol · Intracranial GCT review (ctDNA mentioned peripherally)

T4 — AI/ML in Clinical Diagnostics

Search hits: 28 | Reviewed: 15 | HIGH: 1

🔴 PIPELINE — Score 7

PMID 42420647 · J Imaging Inform Med · 2026-07-08 · DOI
Anatomically Localized Detection of Six Acute Abdominal Emergencies on CT Using Multi-window Deep Learning: Development and Validation
Erdogan HM, Koc U

YOLOv11-L multi-window HU model on 1274-patient national teleradiology dataset; external validation at Stanford Merlin (280 patients, frozen thresholds). Internal macro AUROC 0.941; external 0.879 with all 6 classes ≥0.80; nine-region anatomic localization accuracy 99.5%. Cross-continental validation with clinically interpretable localization.

🟡 WATCH — Score 5

PMID 42418363 · JMIR Form Res · 2026-07-08
AI-CDSS for AKI prevention in ICU (Barcelona, n=202, before-after) — Lower AKI rates observed; causal inference not established; single-center uncontrolled design.

⚪ SKIP — Score 3

PMID 42418931 · Int J Nurs Stud · AI in nursing workflow SR (20 studies, heterogeneous)
PMID 42418609 · NEJM Catal · AI fax document processing at NYU Langone (operational, no clinical outcomes)
PMID 42417639 · Acta Gastroenterol Belg · Pancreatitis radiology review (AI mentioned peripherally)

T5 — Precision Oncology and Genomic Medicine

Search hits: 18 | Reviewed: 15 | HIGH: 1

🔴 PIPELINE — Score 8

PMID 42418202 · JAMA Netw Open · 2026-07-01 · DOI
Germline Multigene Panel Testing in Women With Invasive Lobular Cancer
Corso G, Marino E, Fava F, Natali F, Peterlongo P, Dal Molin M, et al.

Prospective longitudinal cohort at European Institute of Oncology (n=414 ILC, May 2022-Jan 2025, 113-gene NGS panel). PV prevalence: 11.1%; moderate-to-high risk PV carriers: 5-yr BC-free survival 62.2% vs 92.1% (HR 3.91, p<0.001). PRSs non-predictive. First dedicated germline panel study in ILC; 4-fold relapse risk in PV carriers.

⚪ SKIP — Score 4

PMID 42420363 · NPJ Precis Oncol · ATC precision therapy options review (no original data)

T6 — Novel Therapeutics (Immunotherapy, CAR-T, Targeted Therapy)

Search hits: 102 | Reviewed: 15 | HIGH: 3

🔴 PIPELINE — Score 9

PMID 42420295 · Nat Commun · 2026-07-08 · DOI
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma
To V, Thio N, Castle R, Macdonald S, Molden-Hauer T, Wells J, et al.

Prospective Phase I/II RAPPORT trial (NCT02855203, n=30 oligometastatic ccRCC). Pre-existing intratumoural cytotoxic T-cell proximity + post-SABR proliferative CD8+ burst (shared tumor-enriched TCR clones) predicted response to SABR+pembrolizumab. Non-responders: TGF-β/angiogenic immunosuppression. First comprehensive predictive biomarker profile for SABR+anti-PD1 in ccRCC; Nat Commun quality.

🔴 PIPELINE — Score 8

PMID 42419085 · ESMO Open · 2026-07-08 · DOI
Phase II study of trastuzumab-pkrb plus gedatolisib in HER2+ metastatic breast cancer with PI3K pathway alterations
Kim JW, Park YH, Lee S, Ahn HK, Bae J, et al.

Multicenter single-arm Phase II (n=44, ≥2 prior HER2-directed therapies). ORR 43.2% (2 CR+17 PR), DCR 86.4%, median OS 24.74 months. Early ctDNA dynamics predicted PFS and OS. Addresses HER2+/PI3K escape mechanism; dual pathway targeting demonstrates clinical activity.

🔴 PIPELINE — Score 7

PMID 42419879 · J Immunother Cancer · 2026-07-08 · DOI
UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma
Zhang J, Li Y, Chen J, Ma F, Feng B, Zhou S, et al.

Multi-omics (IP-MS, ChIP, scRNA-seq, in vivo) characterization of UXS1-FBXW7-KMT2D-CEBPB-PD-L1 axis in HCC. UXS1 knockout synergizes with anti-PD-1 in mouse models. High UXS1 correlates with low KMT2D, high PD-L1, low CD8+ infiltration in human HCC. Novel immune evasion pathway; potential resistance-reversal target.

🟡 WATCH — Score 5

PMID 42420532 · Nat Rev Drug Discov · 2026-07-08
CAR-T cell therapy for solid cancer scores first approval in China — Landmark regulatory milestone (news item); first solid tumor CAR-T approval globally.

T7 — Cardiovascular-Metabolic (GLP-1, SGLT2, Cardiometabolic Risk)

Search hits: 74 | Reviewed: 15 | HIGH: 2

🔴 PIPELINE — Score 9

PMID 42420795 · Diabetes Obes Metab · 2026-07-08 · DOI
Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists
Chen SC, Wang TJ, Chou CK, Lee C

Retrospective cohort using TriNetX (>192M patients); n=85,546 matched pairs tirzepatide vs semaglutide, n=80,115 semaglutide vs older GLP-1 RAs. Tirzepatide ≈ semaglutide (composite psychiatric HR 0.984 Y1). Semaglutide vs older GLP-1 RAs: depression HR 0.811, anxiety HR 0.915, suicidal ideation HR 0.488 in Y1. Largest comparative neuropsychiatric safety study for newest GLP-1 agents.

🔴 PIPELINE — Score 8

PMID 42420255 · Transl Psychiatry · 2026-07-08 · DOI
GLP-1 receptor agonists for weight management in mental illness: a network meta-analysis
Kishi T, Ikuta T, Sakuma K, Hatano M, Takayanagi T, Suzuki A, Iwata N

NMA of 9 RCTs (n=595, 83.9% schizophrenia spectrum disorders). Semaglutide QW: greatest weight reduction (SMD −2.101 vs control). Liraglutide QD also effective (SMD −0.945). Both reduced HbA1c and waist circumference. First NMA for GLP-1 RAs in psychiatric obesity; semaglutide preferred but sparse network caveat.

🟡 WATCH — Score 6

PMID 42420793 · Diabetes Obes Metab · 2026-07-08
Real-world semaglutide weight management (single GP practice, Denmark, n=206) — 53% discontinued at 12 months; persisters achieved −13.6% weight loss despite under-titration.

T8 — Aging, Longevity, and Population Health

Search hits: 33 | Reviewed: 15 | HIGH: 2

🔴 PIPELINE — Score 8

PMID 42418481 · Proc Natl Acad Sci U S A · 2026-07-14 (epub 2026-07-08) · DOI
Inhibition of elastin degradation alleviates joint degeneration in aging mice, dogs, and human models
Yi J, Xiao X, Zhang H, Xu X, Chen K, Cai X, Zhu Y, et al.

Preclinical multi-model study (aging mice + naturally aging dogs + human cartilage ex vivo). Elastin degradation identified as conserved driver of age-related joint degeneration; pharmacological inhibition reversed degeneration markers across all three model systems. Novel cross-species mechanism; new drug target for OA affecting >500M globally.

🔴 PIPELINE — Score 8

PMID 42417555 · J Cachexia Sarcopenia Muscle · 2026-08-01 · DOI
Metabolic Syndrome as a Determinant of Bidirectional Transitions Between Frailty States: Evidence From the Whitehall II Study
Njouonkep Sime SK, Irie BBAS, Jules E, Fezeu K L, Pujos-Guillot E, Comte B

Whitehall II prospective cohort (n=4,750 adults, mean age 64.6yr, 6.9-yr follow-up); multi-state Markov model with death as absorbing state. Abdominal obesity: increased frailty progression (HR 1.27) and impaired recovery from frailty (HR 0.50). Hyperglycemia reduced prefrailty recovery by 28%. Modifiable metabolic targets for frailty prevention.

T9 — Rare Diseases with High Unmet Need

Search hits: 5 | Reviewed: 5 | HIGH: 1

🔴 PIPELINE — Score 8

PMID 42415941 · Drug Des Devel Ther · 2026-07-03 · DOI
Donidalorsen for the Treatment of Hereditary Angioedema: A Review of Clinical Studies
Riedl MA, Craig T, Lumry WR, Bordone L, Treadwell S, Yarlas A, Newman KB, Cohn DM

Comprehensive review of Phase 1-3 trials (OASIS-HAE Phase 3 RCT + OASISplus OLE). Donidalorsen (GalNAc-ASO targeting plasma prekallikrein) reduced HAE attack rate 81% (Q4W) and 55% (Q8W) vs placebo; sustained 94-95% reduction at 1-year OLE. Monthly SC dosing with acceptable tolerability. Novel molecular mechanism; Phase 3 evidence with 4-year extension.

🟡 WATCH — Score 5

PMID 42420579 · Drugs Real World Outcomes · 2026-07-08
Myasthenia gravis OCS complications (US claims, n=5,827 patients) — 60% higher infection risk, 70% higher osteoporosis risk with 12-month OCS; reinforces steroid-sparing rationale.

⚪ SKIP — Score 4

PMID 42416886 · Clin Immunol Commun · Primary intestinal lymphangiectasia case report + lit review

Sentinel Scan

Search hits: 670 | Reviewed: 10 | HIGH: 0

🟡 WATCH — Score 5

PMID 42420682 · Breast Cancer Res Treat · 2026-07-08 · DOI
Tumor characteristics associated with tomosynthesis versus digital mammography in older women with screen-detected breast cancer
Huang S, Westvold SJ, Soulos PR, Lewin JM, Zhan H, Lustberg MB, Greenup RA, Richman IB, Winer EP, Robinson TJ, Dinan MA

Retrospective comparison of tumor biology features at detection by tomosynthesis vs digital mammography in older women. Addresses whether improved lesion visualization by tomosynthesis reflects clinically meaningful tumor stage differences or potential overdiagnosis in a population-level setting. Timely given widespread tomosynthesis adoption without definitive outcomes data.

Coverage Summary

Generated by PubMed Triage Pipeline v1.3 · Run date: 2026-07-09 · Attempt 1 of 3
Output A: reports/pubmed/run-logs/2026-07-09-attempt1-20260709T090000Z-triage.tmp.json
Output B: reports/pubmed/run-logs/2026-07-09-attempt1-20260709T090000Z-digest.tmp.md